Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety

[Image: see text] Development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene constitutes an effective approach for the treatment of chronic myeloid leukemia (CML) and/or acute lymphoblastic leukemia. However, currently available inhibitors are limited by drug resistance and toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandrala, Mallesh, Bruyneel, Arne Antoon N., Hnatiuk, Anna P., Mercola, Mark, Malhotra, Sanjay V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421657/
https://www.ncbi.nlm.nih.gov/pubmed/35944901
http://dx.doi.org/10.1021/acs.jmedchem.1c01853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421657/
https://www.ncbi.nlm.nih.gov/pubmed/35944901
http://dx.doi.org/10.1021/acs.jmedchem.1c01853

Ejemplares similares